These data demonstrate the emergence of compound 175 as a key tool in the understanding of LRRK2 function and it possible suitability as a potent, highly selective, orally available compound to explore the LRRK2 inhibitor for treatment of Parkinson’s disease (PD). This evidence concerns the gene LRRK2 and Parkinson disease.